Replies to post #10659 on Pluristem Therapeutics Inc (PSTI)

[Straightshot]

Surprising the CELG spinoff did not create some excitement for us given the major backing for cell based therapy... sure it is competition but more importantly it is validity... dare I say we are several years ahead of this new entity but we do need to get a successful trial under our belt to solidify our leading position...

[Melon4head]

To me, it sounds like Tesla or Wrightspeed (microturbine trucks). Lots of hype with future promises... Tesla has been successful especially with the price of their stock!!!

I rarely have seen hype with Pluristem... maybe about 5 years ago when they announced their successes with what I think were 2 patients that had their symptoms resolved from anti cancer therapy and the price shot up to close to $5... I was there...

Without company disclosures being released...there will be little public awareness. The price will flounder where it is now.

But certainly, there is the danger of huge PUBLIC hype and then years of no deliveries. I believe this is the Celgene spinoff.

PSTI IS MILES AHEAD IN THE AREA OF APPROVALS. I mean we have late stage double blind placebo controls studies in huge markets. And let's not forget ARS.

My only concern with PSTI, is the secrecy in releasing data. As I mentioned earlier, my only disappointment is their inability to meet most of their deadlines and not disclosing information in a timely matter....

[EichKing]

For those unwilling to see the big picture and I quote from Fierce Biotech article "Celularity already owns and operates LifeBankUSA, where parents can bank their children's placental stem cells and cord blood, along with the functional regeneration business including BIOVANCE and Interfyl, products made from placenta tissue used to treat severe burns and wounds.

These parts of the business are already set to bring in around $40 million for the company—an unusual bonus for such an early-stage biotech that usually has to wait years for any product/service revenue."....PSTI is not only behind, they are behind with no revenue stream in sight. It is not even a competition without a big pharma partner.